Associated Papers
Gene polymorphism-related differences in the outcomes of abiraterone for prostate cancer: a systematic overview.
Liu M et al.
American Journal of Cancer Research, 2021
Molecular profiling of soft-tissue sarcomas with FoundationOne® Heme identifies potential targets for sarcoma therapy: a single-centre experience.
Scheipl S et al.
Therapeutic Advances in Medical Oncology, 2021
34367342 (PubMed )
Supplement: sj-xlsx-1-tam-10.1177_17588359211029125.xlsx › FMI_Archer
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.
Boysen G et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Select a paper to view details